We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Host Cell Protein Detection in Biomanufacturing
Host cell proteins (HCPs) are critical impurities that must be removed to ensure safety and efficacy of biologic drugs. While broad assays are useful, specific targets like PLBL2, a common CHO-derived impurity linked to immunogenicity and drug degradation, require precise monitoring.
Host Cell Protein - ELISA Kits
Host Cell Protein - Antibodies
Explore our products, articles, and references to strengthen your HCP detection workflows.
Resources
-
Clearer, Cleaner, Stronger: The Buffer Switch That Cut PLBL2 and Elevated Stability.
-
The Complete Guide to Host Cell Protein ELISA - Why It Is Important in Biotherapeutics.
-
Host Cell Protein Detection in Biotherapeutic Manufacturing and the Significance of PLBL2.
-
Quantifying PLBL2 in Biopharmaceutical Purification Using ICL’s CHO PLBL2.
-
Reducing Product Quality Risks in Bioprocessing with Anti-PLBL2 Antibody-Based.
-
Host Cell Protein Detection in Biotherapeutic Manufacturing and the Significance of PLBL2.
Featured Products
Host Cell Protein (HCP) FAQ's
1. What are Host Cell Proteins (HCPs)?
Host Cell Proteins (HCPs) are residual proteins produced by the host cells—such as CHO, E. coli, or yeast—used during the manufacturing of biopharmaceuticals. These proteins are considered process-related impurities and may remain in trace amounts in the final drug product if not adequately removed.
2. Why are HCPs a concern in biopharmaceuticals?
HCPs pose several risks to drug safety and efficacy, including:
- Immunogenicity: HCPs can trigger immune responses, potentially reducing drug effectiveness or causing allergic reactions.
- Adverse Reactions: Some HCPs may directly cause harmful effects in patients.
- Stability Issues: Certain HCPs can degrade the drug product or its excipients, shortening shelf life and compromising quality.
3. How are HCPs removed during manufacturing?
HCP removal is a key objective of downstream purification. Techniques such as chromatography, filtration, and precipitation are employed to selectively isolate the therapeutic protein while eliminating impurities like HCPs.
4. What host cell lines are commonly used in biopharmaceutical production?
Some of the most common host cell lines used include:
- CHO cells: The most widely used, gold standard for producing complex recombinant proteins.
- E. coli: A common bacterial host for the production of simpler proteins.
- Yeast cells(e.g., Pichia pastoris and Saccharomyces cerevisiae)Useful for scalable protein production.
- Insect cells (e.g., Sf9, Hi5)Employed for specific recombinant protein systems.
5. What are some examples of problematic HCPs?
Some HCPs are more problematic than others. A few examples include:
- Phospholipase B-like 2 (PLBL2): A lysosomal enzyme that can degrade therapeutic proteins.
- Legumain: A lysosomal protease that cleave monoclonal antibodies, compromising their integrity.
- Clusterin (CLU): A protein that may bind to antibodies and interfere with their function.
- Lipoprotein Lipase (LPL): An enzyme that can degrade polysorbates, affecting formulation stability.
6. How are HCPs detected and quantified?
The primary method is ELISA (Enzyme-Linked Immunosorbent Assay), which uses antibodies to detect and measure total HCP content. Other techniques include: Western Blotting and Mass Spectrometry.
7. What is an HCP ELISA and how does it work?
An HCP ELISA is a type of immunoassay used to quantify the amount of host cell proteins in a biopharmaceutical product. It works by using a "sandwich" of antibodies. One antibody is coated on a plate and captures the HCPs. A second, enzyme-linked antibody then binds to the captured HCPs. A substrate is added that reacts with the enzyme to produce a color change, and the intensity of the color is proportional to the amount of HCPs present.
8. Why is a robust HCP assay important?
A well-developed HCP assay ensures:
- Patient Safety: By confirming HCP levels are within safe limits.
- Regulatory Compliance: Required by agencies like the FDA and EMA.
- Process Optimization: HCP assays are used to monitor the effectiveness of the purification process and make improvements.
- Product Quality: Ensuring low levels of HCPs contributes to the overall quality, safety, and efficacy.
9. What are the challenges in developing a quality HCP assay?
Developing a robust HCP assay can be challenging due to the complexity and diversity of HCPs. Some of the challenges include:
- Coverage: Ensuring that the assay can detect the wide range of different HCPs present.
- Sensitivity: The assay needs to be sensitive enough to detect very low levels of HCPs.
- Specificity: The assay should only detect HCPs and not the drug product or other components of the sample.
- Antibody Development: Developing antibodies that can recognize the full range of HCPs is a complex process.
10. What are the regulatory guidelines for HCPs?
Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines for the control and monitoring of HCPs in biopharmaceuticals. These guidelines require manufacturers to:
- Develop and validate sensitive, specific HCP assays.
- Define acceptable HCP limits in the final product.
- Monitor HCP levels throughout the manufacturing process.
- Perform a risk assessment to evaluate the potential impact of HCPs on patient safety.
References / Citations
1. E-65PLB
Lakatos, D., Idler, M., Stibitzky, S., Amann, J., Schuschkewitz, J., Krayl, D., Liebau, J., Grosch, J.-H., Arango Gutierrez, E., & Kluters, S. (2024). Buffer System Improves the Removal of Host Cell Protein Impurities in Monoclonal Antibody Purification. Biotechnology and Bioengineering, 1–12. https://doi.org/10.1002/bit.28844
Falkenberg H, Waldera-Lupa DM, Vanderlaan M, Schwab T, Krapfenbauer K, Studts JM, Flad T, Waerner T. Mass spectrometric evaluation of upstream and downstream process influences on host cell protein patterns in biopharmaceutical products. Biotechnol Prog. 2019 May;35(3):e2788. doi: 10.1002/btpr.2788. Epub 2019 Mar 6. PMID: 30767403.
2. AG65-0324-Z
Dolan ME, Tedeschi A, Oppenheim SF, and Zhou ZS. Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of Problematic Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Northeastern University Department of Chemistry and Chemical Biology, Takeda Development Center Americas, Inc. December 09, 2024
AG65-0324
3. MPLB-65ALY-Z-4D5
Dolan ME, Tedeschi A, Oppenheim SF, and Zhou ZS. Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of Problematic Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Northeastern University Department of Chemistry and Chemical Biology, Takeda Development Center Americas, Inc. December 09, 2024
Dolan, M. E., Wang, L., Tedeschi, A., Wang, Y., Barton, C., Oppenheim, S. F., & Zhou, Z. S. (2025). Elucidation of proteoforms of Chinese hamster ovary (CHO) phospholipase B‐like 2 (PLBL2) captured from a monoclonal antibody. Biotechnology and Bioengineering, 1–14. https://doi.org/10.1002/bit.70104
4. AG65-0324-Z
Dolan ME, Tedeschi A, Oppenheim SF, and Zhou ZS. Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of Problematic Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Northeastern University Department of Chemistry and Chemical Biology, Takeda Development Center Americas, Inc. December 09, 2024
AG65-0324
5. AG65-035-Z
Dolan ME, Tedeschi A, Oppenheim SF, and Zhou ZS. Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of Problematic Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Northeastern University Department of Chemistry and Chemical Biology, Takeda Development Center Americas, Inc. December 09, 2024
AG65-035
6. AG65-0365-Z
Dolan ME, Sadiki A, Wang LL, Wang Y, Barton C, Oppenheim SF, Zhou ZS. First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region. Antib Ther. 2024 Jul 10;7(3):233-248. doi: 10.1093/abt/tbae014. PMID: 39262442; PMCID: PMC11384149.
Dolan ME, Tedeschi A, Oppenheim SF, and Zhou ZS. Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of Problematic Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Northeastern University Department of Chemistry and Chemical Biology, Takeda Development Center Americas, Inc. December 09, 2024
Dolan, M. E., Wang, L., Tedeschi, A., Wang, Y., Barton, C., Oppenheim, S. F., & Zhou, Z. S. (2025). Elucidation of proteoforms of Chinese hamster ovary (CHO) phospholipase B‐like 2 (PLBL2) captured from a monoclonal antibody. Biotechnology and Bioengineering, 1–14. https://doi.org/10.1002/bit.70104
7. GPLB-65B-Z
Michael E. Dolan, Alexander Tedeschi, Sheldon F. Oppenheim, and Zhaohui Sunny Zhou Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of Problematic Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Northeastern University Department of Chemistry and Chemical Biology, Takeda Development Center Americas, Inc. December 09, 2024
8. GPLB-65ALY
Dolan ME, Sadiki A, Wang LL, Wang Y, Barton C, Oppenheim SF, Zhou ZS. First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region. Antib Ther. 2024 Jul 10;7(3):233-248. doi: 10.1093/abt/tbae014. PMID: 39262442; PMCID: PMC11384149.
Dolan ME, Tedeschi A, Oppenheim SF, and Zhou ZS. Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of Problematic Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Northeastern University Department of Chemistry and Chemical Biology, Takeda Development Center Americas, Inc. December 09, 2024
Dolan, M. E., Wang, L., Tedeschi, A., Wang, Y., Barton, C., Oppenheim, S. F., & Zhou, Z. S. (2025). Elucidation of proteoforms of Chinese hamster ovary (CHO) phospholipase B‐like 2 (PLBL2) captured from a monoclonal antibody. Biotechnology and Bioengineering, 1–14. https://doi.org/10.1002/bit.70104
9. MPLB-65ALY-4D5
Dolan ME, Tedeschi A, Oppenheim SF, and Zhou ZS. Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of Problematic Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2) Northeastern University Department of Chemistry and Chemical Biology, Takeda Development Center Americas, Inc. December 09, 2024
